Opus Genetics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Opus Genetics, Inc. (IRD) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 3.10% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2023-03-30
- Opus Genetics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 3.10%, a 181.82% increase from fiscal 2021.
- Opus Genetics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was 1.10%.
- Opus Genetics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2020 was -1.10%.
- Opus Genetics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2019 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month as first filed |
|---|---|---|
| 2022-12-31 | 3.10% 10-K · filed 2023-03-30 | |
| 2021-12-31 | 1.10% 10-K · filed 2023-03-30 | -1.10% 10-K · filed 2022-03-24 |
| 2020-12-31 | -1.10% 10-K · filed 2022-03-24 | |
| 2019-12-31 | 0.00% 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |